


## Supplementary Information


### ***Supplementary Fig. 1. Spatial mapping of MEP progenitors at the single cell level.***

a) Heatmap displays relative gene expression levels of top 10 DEGs per cluster in 18,678 MEP cells grouped by cluster, color-coded according to t-SNE plot in Fig. 1a (higher, yellow; lower, pink). b) Bar graphs show significant overlap ( $-\log(p\text{-value})$ ) between DEGs of cluster 8 (top) and cluster 9 (bottom) with genes sets related to stroma and vasculature/immune cells, respectively, from the Molecular Signatures Database. c) Cluster-assigned bubble plot of luminal (*KRT15*, *KRT19*, *SLPI*, *LTF*, *CD24*) and MEP markers (*KRT5*, *KRT14*, *KRT17*, *MYLK*, *ACTA2*, *TP63*) shows up-regulation of luminal genes in cluster 7 and MEP genes in clusters 0 to 6 indicating that the first seven clusters are true MEP clusters.


**Supplementary Fig. 1. Spatial mapping of MEP progenitors at the single cell level**




**Cluster 8**



**Cluster 9**



**b**




**c**


**Supplementary Fig. 2. CD200 is a marker for a distinct MEP subpopulation.**

a) Representative contour FACS plots of pre-sorted myoepithelial cells from eight different human normal breast biopsies illustrate biopsy-dependent variability in CD271 and CD200 expression. b) (upper panel) Multicolor images of cryosections of TDLU, duct (20x), and terminal duct (TD, 40x) stained for SMA with HHF-35 (green), CD200 (red) and nuclei (blue) show accumulation of CD200<sup>high</sup> cells in terminal duct versus alveoli and duct (scale bar, 100  $\mu$ m for TDLU and duct and 50  $\mu$ m for terminal duct). (lower panel) Schematic overview of distribution of CD200<sup>low</sup> (blue) and CD200<sup>high</sup> (red) MEP in alveoli (Alv) and terminal duct (TD) of micro-collected TDLU and duct.

**Supplementary Fig. 2. CD200 is a marker for a distinct MEP subpopulation**




SMA/CD200/nuclei



micro-collected TDLU

micro-collected duct




Alv: Alveoli  
TD: Terminal Duct

**b**


**Supplementary Fig. 3. Myo<sup>+</sup> conditions support ground state of MEP progenitors poised for luminal differentiation.**

a) Bar graph depicts quantification of frequency of  $\alpha$ -SMA-positive cells (%  $\alpha$ -SMA positive cells) in passage 1 to 4 of Trop2<sup>+</sup>/CD271<sup>high</sup> myoepithelial cells from a biopsy with initial high frequency of  $\alpha$ -SMA MEP on iHBFC<sup>CD105</sup> feeders. Under control conditions (Myo, black)  $\alpha$ -SMA expression decreases in passages 3 and 4, while in Myo medium with IFN $\alpha$  and 1% oxygen (medium grey), a significantly higher expression of  $\alpha$ -SMA is seen in passage 3 and 4 compared to Myo medium (\*p<0.05 for P3 and \*\*\*p<0.005 for P4 by two-way ANOVA and Tukey's multiple comparison test). When cultured with IFN $\alpha$ , RepSox, and under hypoxic conditions (Myo<sup>+</sup>, dark grey),  $\alpha$ -SMA expression is significantly increased in all passages compared to Myo medium (\*\*\*p<0.005 by two-way ANOVA and Tukey's multiple comparison test). Bars indicate mean  $\pm$  standard deviation (n = 3 regions in MEP cell culture). b) Micrographs of primary CD200<sup>high</sup> MEP cells stained for K14 (green), K19 (red) and  $\alpha$ -SMA (red) show maintenance of K14<sup>+</sup>/K19<sup>-</sup> and K14<sup>+</sup>/ $\alpha$ -SMA<sup>+</sup> MEP progenitors in Myo<sup>+</sup> conditions (Myo<sup>+</sup> (Ground state)). Upon induced luminal differentiation in MEGM with A83-01 (MEGM<sup>+</sup> (Differentiated)), the K14<sup>+</sup>/K19<sup>-</sup> phenotype is maintained (first column), but in addition, colonies comprising K14<sup>+</sup>/K19<sup>+</sup> (second column), but not K14<sup>-</sup>/K19<sup>+</sup>, appear (scale bar, 100  $\mu$ m).

**Supplementary Fig. 3. Myo<sup>+</sup> conditions support ground state of MEP progenitors poised for luminal differentiation**



**a**




**b**

**Supplementary Fig. 4. CD200<sup>low</sup> and CD200<sup>high</sup> MEP progenitors have distinct differentiation repertoires.**

a) Bar graphs of quantification of frequency (% cells) of myodifferentiated ( $\alpha$ -SMA, light colors), K14<sup>+</sup>/K19<sup>+</sup> (medium) and K14<sup>-</sup>/K19<sup>+</sup> (dark colors) cells among CD200<sup>low</sup> (blue) and CD200<sup>high</sup> (red) cells in ground state (Myo<sup>+</sup>) and upon differentiation (MEGM<sup>+</sup>), respectively, show a significantly higher frequency of luminal K14<sup>-</sup>/K19<sup>+</sup> cells in CD200<sup>low</sup> cultures. Bars indicate mean  $\pm$  SEM ( $p < 0.01$  by two-tailed Mann-Whitney test,  $n = 7$  for Myo<sup>+</sup> and  $n = 6$  for MEGM<sup>+</sup> experiments representing four biopsies). b) Bar graph of fold change of normalized gene expression by RT-qPCR. Upon differentiation (MEGM<sup>+</sup>, dark shade) CD200<sup>low</sup> (blue) and CD200<sup>high</sup> (red) both respond with reduced *KRT14* and *TP63* and increased *EPCAM* expression, but a significantly higher upregulation of *ELF5* and *KRT19* is observed in CD200<sup>low</sup>. Bars indicate mean  $\pm$  SEM (\*\*\* $p < 0.005$  by two-way ANOVA and Tukey's multiple comparison test,  $n = 3$ ). c) Micrograph of primary CD200<sup>low</sup> MEP cells stained for K19 (green) and ER (red) upon culture in ER-supporting conditions shows that CD200<sup>low</sup> MEP cells are able to express ER (scale bar, 100  $\mu$ m).

**Supplementary Fig. 4.  $CD200^{low}$  and  $CD200^{high}$  MEP progenitors have distinct differentiation repertoires**






**Supplementary Fig. 5. A sequential transduction protocol provides identical growth rates with and without mutant PIK3CA.**

a) Line drawing of passage number (P) for transduction of CD200<sup>low</sup> (blue) and CD200<sup>high</sup> (red) with *hTERT*, shp53 and *PIK3CA*<sup>H1047R</sup>, respectively, with indication of the number of passages the cell strains have been cultured. b) Diagram of the calculated population doublings as a function of time (days) for untransfected CD200<sup>low</sup> (blue, diamond) and CD200<sup>high</sup> (red, diamond), in comparison with *hTERT* transfected (squares), *hTERT*-shp53 transfected (triangles) and *hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (circles). *hTERT* extends the lifespan of the cells, albeit not increasing the growth rate, while further transfection with either shp53, or shp53 and *PIK3CA*<sup>H1047R</sup> decreases the population doubling time considerably and to a similar degree in both CD200<sup>low</sup> and CD200<sup>high</sup>. c) Bar graphs of fold change of normalized gene expression in CD200<sup>low</sup> and CD200<sup>high</sup> strains by qRT-PCR confirm significant silencing of *TP53* in *hTERT*-shp53 and *hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> transfected cell strains as compared to *hTERT* transfected cell strains, and a significantly higher expression of *PIK3CA* in *hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> as compared to *hTERT* and *hTERT*-shp53 transfected cells strains. Bars indicate mean  $\pm$  SEM (\*\*\*) $p < 0.005$  by two-way ANOVA and Tukey's multiple comparison test, n = 3).




**Supplementary Fig. 5. A sequential transduction protocol provides identical growth rates with and without mutant PIK3CA**



**Supplementary Fig. 6. Mutant PIK3CA destabilizes ground state phenotype without affecting differentiation repertoire.**

a) Micrographs of fluorescence stainings of (left) CD200<sup>low</sup>-*hTERT*-shp53 and (right) CD200<sup>high</sup>-*hTERT*-shp53 without (-) or with (+) mutant *PIK3CA* (*PIK3CA*<sup>H1047R</sup>) in Myo<sup>+</sup> (Ground state) show maintenance of K14 (green), p63 (red), and K17 (red) expression upon *PIK3CA*<sup>H1047R</sup> expression in both cell lines (scale bar, 50  $\mu$ m). b) Bar graph of fold change of normalized relative gene expression in CD200<sup>low</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (blue) and CD200<sup>high</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (red) lines assessed by RT-qPCR shows higher expression of cluster 3 markers *CD200*, *AMIGO2*, *ACTA2*, and *FAM126A* is maintained in the CD200<sup>high</sup> cell line compared to the CD200<sup>low</sup> cell line. Similarly, CD200<sup>low</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> retains higher expression of *TXNIP*, *RARRES1*, and *TNFSF10* compared to CD200<sup>high</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup>. Bars indicate mean  $\pm$  SEM (\*\*\*)  $p < 0.005$  by multiple unpaired t tests with Bonferroni correction,  $n = 4$  cultures in different passages). c) Representative micrographs of peroxidase staining of (left) CD200<sup>low</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> and (right) CD200<sup>high</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> after differentiation show a relatively broad expression of the luminal marker FOXA1, while expression of the ER-associated protein GATA3 is restricted to CD200<sup>low</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (scale bar, 50  $\mu$ m).

**Supplementary Fig. 6. Mutant PIK3CA destabilizes ground state phenotype without affecting differentiation repertoire**



***Supplementary Fig. 7. Mutant PIK3CA transformed CD200<sup>low</sup> and CD200<sup>high</sup> MEP cells maintain correct polarization.***


Micrographs of fluorescence staining of cryosections stained for integrin  $\beta$ 4 (ITGB4, green), mucin 1 (MUC1, red) and nuclei (blue) of structures formed in rBM by CD200<sup>low</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (CD200<sup>low</sup>) and CD200<sup>high</sup>-*hTERT*-shp53-*PIK3CA*<sup>H1047R</sup> (CD200<sup>high</sup>) cells (scale bar, 50  $\mu$ m).

**Supplementary Fig. 7. Mutant PIK3CA transformed CD200<sup>low</sup> and CD200<sup>high</sup> MEP cells maintain correct polarization**

CD200<sup>low</sup>

CD200<sup>high</sup>

ITGB4/MUC1/Nuclei



***Supplementary Table 1. Overview of cell numbers and their anatomical origins in MEP clusters.***

Table shows absolute cell numbers and percentages per cluster as well as cell numbers contributed from TDLUs and ducts.

**Supplementary Table 1. Overview of cell numbers and their anatomical origins in MEP clusters**

<b>Cluster</b>	<b>Cell number</b>	<b>%</b>	<b>TDLU-derived</b>	<b>Duct-derived</b>
0	3670	19.6%	2146	1524
1	3608	19.3%	2087	1521
2	3071	16.4%	1583	1488
3	2641	14.1%	1880	761
4	2534	13.6%	1744	790
5	2322	12.4%	1233	1089
6	449	2.4%	264	185
7	174	0.9%	50	124
8	158	0.8%	113	45
9	51	0.3%	33	18
<b>Sum</b>	<b>18678</b>	<b>100%</b>	<b>11133</b>	<b>7545</b>



***Supplementary Table 2. Overview of estimated cell numbers from TDLUs and ducts from each of three biopsies.***

Table shows donor age, estimated cell number before and after quality control (QC) and filtration as well as median genes per cell before and after QC and filtration for scRNA-seq.

**Supplementary table 2. Overview of estimated cell numbers from TDLUs and ducts from each of three biopsies**

<b>Biopsy</b>	<b>Age</b>	<b>Location</b>	<b>Estimated number of cells</b>	<b>Number of cells after QC and filtration</b>	<b>Median genes per cell</b>	<b>Median genes per cell after QC and filtration</b>
1	18	TDLUs	4,034	3,617	1,256	1,278
		Ducts	4,766	4,647	1,057	1,058
2	18	TDLUs	6,821	6,398	1,130	1,142
		Ducts	1,742	1,258	2,054	1,905
3	18	TDLUs	3,653	1,640	2,209	1,941
		Ducts	3,230	1,118	1,961	2,057
Total			24,246	18,678		1,259

***Supplementary Table 3. Overview of antibodies used for immunofluorescence staining of cultured cells and tissue sections.***

Table lists clones, companies, catalogue numbers, and dilutions of antibodies used for immunofluorescence.

**Supplementary Table 3. Overview of antibodies used for immunofluorescence staining of cultured cells and tissue sections**

Antigen	Clone	Company	Cat. No.	Dilution
K14	LL002	Monosan	MONX10687	1:100
$\alpha$ -SMA	1A4	Sigma-Aldrich	A-2547	1:500
$\alpha$ - $\gamma$ -SMA	HHF35	Enzo	ENZ-30931	1:25
K19	Ba16	Abcam	ab20210	1:100/1:300
K19	A53-B/A2	Abcam	ab7754	1:300
K17	E3	Dako	M7046	1:100
CD200	EPR22412229	Abcam	ab254193	1:50
AMIGO2	S86-36	Novus Biologicals	NBP2-22413	1:100
K5	XM26	Novocastra	NCL-CK5	1:250
K8/18	Troma-I	DSHB	Troma-I	1:100
P63	7JUL	Novocastra	NCL-L-P63	1:50
K7	OV-TL 12/30	Dako	M7018	1:300
ITGB4	3E1	Chemicon	MAB1964	1:500
MUC1	115D8	Biogenesis	0200-0101	1:10
ER	SP1	Epredia	RM-9101-S	1:25
FOXA1	JF10-02	Invitrogen	MA5-32556	1:200
GATA3	HG3-31	Santa Cruz	sc-268	1:200
AF488 Anti-mouse IgG1		Invitrogen	A21121	1:500
AF488 Anti-mouse IgG2b		Invitrogen	A21141	1:500
AF488 Anti-mouse IgG3		Invitrogen	A21151	1:500
AF568 Anti-mouse IgG1		Invitrogen	A21124	1:500
AF568 Anti-mouse IgG2a		Invitrogen	A21134	1:500
AF568 Anti-mouse IgG2b		Invitrogen	A21144	1:500
AF568 Anti-rat		Molecular Probes	A11077	1:500
AF633 Anti-mouse IgG3		Molecular Probes	A21156	1:500